본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The American journal of medicine v.130 no.2, 2017년, pp.173 - 187   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Role of Niacin in Current Clinical Practice: A Systematic Review

Garg, Aakash (Department of Medicine, St. Peter's University Hospital, Rutgers/Robert Wood Johnson Medical School, New Brunswick, NJ ) ; Sharma, Abhishek (Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, NY ) ; Krishnamoorthy, Parasuram (Department of Cardiovascular Medicine, Albert Einstein Medical Center, Philadelphia, Penn ) ; Garg, Jalaj (Department of Cardiology, Lehigh Valley Health Network, Allentown, Penn ) ; Virmani, Deepti (Department of Medicine, Albert Einstein College of Medicine, Bronx, NY ) ; Sharma, Toishi (Department of Medicine, Cleveland Clinic, Weston, Fla ) ; Stefanini, Giulio (Division of Cardiology, Humanitas Research Hospital, Rozzano, Italy ) ; Kostis, John B. (Division of Cardiology, Cardiovascular Institute, Rutgers/Robert Wood Johnson Medical School, New Brunswick, NJ ) ; Mukherjee, Debabrata (Division of Cardiology, Texas Tech University, El Paso, Tex ) ; Sikorskaya, Ekaterina (Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY ) ;
  • 초록  

    Abstract Background Niacin, a potent high-density lipoprotein cholesterol-raising drug, seems an attractive approach to reduce cardiac events in patients with or at risk of atherosclerotic cardiovascular disease. However, previous evidence for niacin has been challenged recently by negative outcomes in 2 large, randomized, controlled trials comparing niacin to placebo with background statin therapy. We studied the currently available evidence for the role of niacin treatment for reducing the risk of cardiovascular events in current practice. Methods A systematic review of randomized controlled trials in the MEDLINE, EMBASE, CINAHL, and Cochrane databases comparing niacin alone or combined with statin therapy was performed. We extracted trial level data, including basic characteristics and number of patients enrolled, duration of follow up, occurrence of adverse events, and cardiovascular-related outcomes. Random effects meta-analysis was conducted to estimate the risk ratio (RR) for individual trial endpoints. Results Thirteen trials (N = 35,206) were selected for final analysis. The mean follow-up duration was 32.8 months. Overall, niacin led to significant increases in serum high-density lipoprotein cholesterol levels from baseline trial enrolment by 21.4%, 9.31 (95% confidence interval [CI] 5.11-13.51) mg/dL. However, we did not observe any differences in all-cause mortality rates (RR 0.99; 95% CI 0.88-1.12) between niacin and control arms. Further, niacin treatment was associated with a trend toward lower risk of cardiovascular mortality (RR 0.91; 95% CI 0.81-1.02), coronary death (RR 0.93; 95% CI 0.78-1.10), nonfatal myocardial infarction (RR 0.85; 95% CI 0.73-1.0), revascularization (coronary and noncoronary) (RR 0.83; 95% CI 0.65-1.06), and stroke (RR 0.89; 95% CI 0.72-1.10), compared with control. Conclusion Niacin therapy does not lead to significant reductions in total or cause-specific mortality or recurrent cardiovascular events among persons with or at risk of atherosclerotic cardiovascular disease.


  • 주제어

    Cardiovascular risk .   High-density lipoprotein cholesterol .   Niacin.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기